Abstracts patients who begin with low and high levels and regardless of final level achieved. METHODS: A cohort of 27,660 patients with coronary artery disease, peripheral vascular disease, or diabetes mellitus were selected and followed retrospectively for their first myocardial infarction or revascularization recorded in the New England Veterans Affairs database. Pre-outcome low-density lipoprotein cholesterol reduction was categorized as follows: <10 mg/dl, reference; 10-39 mg/dl, small reduction; 40-69 mg/dl, moderate reduction; >70 mg/dl, large reduction. Cox proportional hazards was used to determine hazard ratios for each category of lipid reduction compared to reference and stratified by high or low initial LDL-C, adjusting for initial LDL-C, statin use, age, gender, and co morbidities. RESULTS: Among patients with initial LDL-C above the median of 133 mg/dL, hazard ratios (95% confidence intervals) for small, moderate, and large reductions compared to reference were 0.90 (0.85-0.96), 0.84 (0.79-0.90), and 0.76 (0.70-0.83) respectively. A total of 3448 or 24% of such patients achieved a final level <100 mg/dL. Among patients with initial levels below the median, hazard ratios (95% confidence intervals) for small, moderate, and large reductions were 0.90 (0.85-0.96), 0.87 (0.79-0.96), and 0.76 (0.56-1.05) respectively. A total of 5492 or 40% of such patients achieved final level <100 mg/dL. CON-CLUSION: These data suggest that magnitude of reduction in low-density lipoprotein cholesterol is proportional to degree of reduction in cardiovascular risk, and that this effect holds both for patients with initially low or high lipid levels, regardless of whether a final LDL-C of <100 mg/dL was achieved. Euroclin Institute, Alcobendas, Madrid, Spain OBJECTIVES: The lipid-lowering arm of ASCOT demonstrated that in hypertensive patients, in primary prevention who are not conventionally deemed dyslipidaemic and with at least three cardiovascular risk factors (CVRF), atorvastatin ten mg conferred a reduction in CV morbimortality. There are no data regarding the prevalence of these patients among the hypertensives in Spain. The objective is to determine the prevalence of the patient as defined in the ASCOT among the Spanish hypertensives. METHODS: Data from 2004 to 2005 of 6309 hypertensives from Spanish primary care centres were studied. We analyzed the following variables: left-ventricular hypertrophy, other specified abnormalities on EKG, type 2 diabetes, peripheral arterial disease, previous stroke, gender, age, microalbuminuria, smoking, ratio total cholesterol/HDL-cholesterol, and premature family history of CHD. We analyzed the Number of CVRF as defined in ASCOT and the percentage of patients with CVRF ≥3 (with normal TC and in primary prevention). RESULTS: Of the 6309 patients, 2528 (40%) had history of CHD and/or heart failure and/or TC >250 mg/dl and/or a statin treatment. The presence of ASCOT-CVFR ≥3 was analyzed in the 3781 remaining ones. The percentage of additional CVRF relative to these 3781 patients was: 0 FRCV: 4.3%; 1 FRCV: 24.6%; 2 FRCV: 30.4%; 3 FRCV: 22.2%; 4 FRCV: 11.8%; 5FRCV: 5.1%; 6 FRCV: 1.3%; 7 FRCV: 0.3%; 8 FRCV: 0.03%. There were 1540 patients (40.7%) with CVRF ≥3. This percentage, in relation to the whole population of hypertensives (6309) was 24.4%. CON-CLUSIONS: Because of the retrospective nature of the design, it is advisable to be prudent in the external generalization. Nevertheless a high prevalence (at least 40.7%) of the ASCOT-patient (CVRF ≥3), relative to a population of Spanish hypertensive patients in primary prevention, not treated with statins and with total cholesterol ≤250 mg/dL, have been demonstrated. [ECV]) and clinical parameters (systolic blood pressure, diastolic blood pressure, LDLc, HbA1c). Therapeutic control goals were established according to NCEP-ATP III. A bivariant analysis and a binary logistic regression model were performed to fit the model. The statistical program SPSS was used with a 5% significance level. RESULTS: A total of 15,470 patients had at least one CVRF. Mean age was 61.3 ± 14.3; 53.7% were female and 14.2% had a history of CVD. The diagnosis was hypertension in 60.6%, diabetes in 26.7% and hipercolesterolemia in 49.5%. The presence of CVRF >3 was confirmed in 5.8% and CVD in 28.3%. The percentage of patients who
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